{"pmid":32293833,"title":"EMERGING AND REEMERGING RESPIRATORY VIRAL INFECTIONS UP TO COVID-19.","text":["EMERGING AND REEMERGING RESPIRATORY VIRAL INFECTIONS UP TO COVID-19.","Infectious diseases remain as the significant causes of human and animal morbidity and mortality, leading to extensive outbreaks and epidemics. Acute respiratory viral diseases claim over four million deaths and cause millions of hospitalizations in developing countries every year. Emerging viruses, especially the RNA viruses, are more pathogenic since most people have no herd immunity. The RNA viruses can adapt to the rapidly changing global and local environment due to the high error rate of their polymerases that replicate their genomes. Currently, Coronavirus disease 2019 (COVID-19) is determined as an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified in 2019 in Wuhan. Herein we discuss emerging and reemerging respiratory viral infections till to SARS-CoV-2.","Turk J Med Sci","Celik, Ilhami","Saatci, Esma","Eyuboglu, Aysegul Fusun","32293833"],"abstract":["Infectious diseases remain as the significant causes of human and animal morbidity and mortality, leading to extensive outbreaks and epidemics. Acute respiratory viral diseases claim over four million deaths and cause millions of hospitalizations in developing countries every year. Emerging viruses, especially the RNA viruses, are more pathogenic since most people have no herd immunity. The RNA viruses can adapt to the rapidly changing global and local environment due to the high error rate of their polymerases that replicate their genomes. Currently, Coronavirus disease 2019 (COVID-19) is determined as an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified in 2019 in Wuhan. Herein we discuss emerging and reemerging respiratory viral infections till to SARS-CoV-2."],"journal":"Turk J Med Sci","authors":["Celik, Ilhami","Saatci, Esma","Eyuboglu, Aysegul Fusun"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293833","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-126","keywords":["Covid-19","Emerging","Reemerging","Respiratory virus"],"source":"PubMed","weight":0,"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266295598645249,"score":8.233237,"similar":[{"pmid":32196426,"title":"Seasonality of Respiratory Viral Infections.","text":["Seasonality of Respiratory Viral Infections.","The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during the winter months. The mechanisms underlying the seasonal nature of respiratory viral infections have been examined and debated for many years. The two major contributing factors are the changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of the environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract. Here we review evidence of how outdoor and indoor climates are linked to the seasonality of viral respiratory infections. We further discuss determinants of host response in the seasonality of respiratory viruses by highlighting recent studies in the field. Expected final online publication date for the Annual Review of Virology, Volume 7 is September 29, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","Annu Rev Virol","Moriyama, Miyu","Hugentobler, Walter J","Iwasaki, Akiko","32196426"],"abstract":["The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during the winter months. The mechanisms underlying the seasonal nature of respiratory viral infections have been examined and debated for many years. The two major contributing factors are the changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of the environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract. Here we review evidence of how outdoor and indoor climates are linked to the seasonality of viral respiratory infections. We further discuss determinants of host response in the seasonality of respiratory viruses by highlighting recent studies in the field. Expected final online publication date for the Annual Review of Virology, Volume 7 is September 29, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates."],"journal":"Annu Rev Virol","authors":["Moriyama, Miyu","Hugentobler, Walter J","Iwasaki, Akiko"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196426","week":"202012|Mar 16 - Mar 22","doi":"10.1146/annurev-virology-012420-022445","source":"PubMed","topics":["Transmission"],"weight":1,"_version_":1663352133556109312,"score":211.12927},{"pmid":32210130,"title":"Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2.","text":["Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2.","Over the last two decades, the world experienced three outbreaks of coronaviruses with elevated morbidity rates. Currently, the global community is facing emerging virus SARS-CoV-2 belonging to Betacoronavirus, which appears to be more transmissible but less deadly than SARS-CoV. The current study aimed to track the evolutionary ancestors and different evolutionary strategies that were genetically adapted by SARS-CoV-2. Our whole-genome analysis revealed that SARS-CoV-2 was the descendant of Bat SARS/SARS-like CoVs and bats served as a natural reservoir. SARS-CoV-2 used mutations and recombination as crucial strategies in different genomic regions including the envelop, membrane, nucleocapsid, and spike glycoproteins to become a novel infectious agent. We confirmed that mutations in different genomic regions of SARS-CoV-2 have specific influence on virus reproductive adaptability, allowing for genotype adjustment and adaptations in rapidly changing environments. Moreover, for the first time we identified nine putative recombination patterns in SARS-CoV-2, which encompass spike glycoprotein, RdRp, helicase and ORF3a. Six recombination regions were spotted in the S gene and are undoubtedly important for evolutionary survival, meanwhile this permitted the virus to modify superficial antigenicity to find a way from immune reconnaissance in animals and adapt to a human host. With these combined natural selected strategies, SARS-CoV-2 emerged as a novel virus in human society.","Pathogens","Rehman, Saif Ur","Shafique, Laiba","Ihsan, Awais","Liu, Qingyou","32210130"],"abstract":["Over the last two decades, the world experienced three outbreaks of coronaviruses with elevated morbidity rates. Currently, the global community is facing emerging virus SARS-CoV-2 belonging to Betacoronavirus, which appears to be more transmissible but less deadly than SARS-CoV. The current study aimed to track the evolutionary ancestors and different evolutionary strategies that were genetically adapted by SARS-CoV-2. Our whole-genome analysis revealed that SARS-CoV-2 was the descendant of Bat SARS/SARS-like CoVs and bats served as a natural reservoir. SARS-CoV-2 used mutations and recombination as crucial strategies in different genomic regions including the envelop, membrane, nucleocapsid, and spike glycoproteins to become a novel infectious agent. We confirmed that mutations in different genomic regions of SARS-CoV-2 have specific influence on virus reproductive adaptability, allowing for genotype adjustment and adaptations in rapidly changing environments. Moreover, for the first time we identified nine putative recombination patterns in SARS-CoV-2, which encompass spike glycoprotein, RdRp, helicase and ORF3a. Six recombination regions were spotted in the S gene and are undoubtedly important for evolutionary survival, meanwhile this permitted the virus to modify superficial antigenicity to find a way from immune reconnaissance in animals and adapt to a human host. With these combined natural selected strategies, SARS-CoV-2 emerged as a novel virus in human society."],"journal":"Pathogens","authors":["Rehman, Saif Ur","Shafique, Laiba","Ihsan, Awais","Liu, Qingyou"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32210130","week":"202013|Mar 23 - Mar 29","doi":"10.3390/pathogens9030240","keywords":["SARS-CoV","SARS-CoV-2","evolutionary strategies","genomic structure","mutations","phylogeny","recombination or reassortment"],"source":"PubMed","topics":["Mechanism","Transmission"],"weight":1,"_version_":1663352134923452416,"score":193.36078},{"pmid":32015508,"pmcid":"PMC7094943","title":"A new coronavirus associated with human respiratory disease in China.","text":["A new coronavirus associated with human respiratory disease in China.","Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health(1-3). Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty. A severe respiratory disease was recently reported in Wuhan, Hubei province, China. As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan. Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough. Metagenomic RNA sequencing(4) of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV'). Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China(5). This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.","Nature","Wu, Fan","Zhao, Su","Yu, Bin","Chen, Yan-Mei","Wang, Wen","Song, Zhi-Gang","Hu, Yi","Tao, Zhao-Wu","Tian, Jun-Hua","Pei, Yuan-Yuan","Yuan, Ming-Li","Zhang, Yu-Ling","Dai, Fa-Hui","Liu, Yi","Wang, Qi-Min","Zheng, Jiao-Jiao","Xu, Lin","Holmes, Edward C","Zhang, Yong-Zhen","32015508"],"abstract":["Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health(1-3). Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty. A severe respiratory disease was recently reported in Wuhan, Hubei province, China. As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan. Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough. Metagenomic RNA sequencing(4) of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV'). Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China(5). This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans."],"journal":"Nature","authors":["Wu, Fan","Zhao, Su","Yu, Bin","Chen, Yan-Mei","Wang, Wen","Song, Zhi-Gang","Hu, Yi","Tao, Zhao-Wu","Tian, Jun-Hua","Pei, Yuan-Yuan","Yuan, Ming-Li","Zhang, Yu-Ling","Dai, Fa-Hui","Liu, Yi","Wang, Qi-Min","Zheng, Jiao-Jiao","Xu, Lin","Holmes, Edward C","Zhang, Yong-Zhen"],"date":"2020-02-05T11:00:00Z","year":2020,"_id":"32015508","week":"20206|Feb 03 - Feb 09","doi":"10.1038/s41586-020-2008-3","link_comment_in":"32020126","source":"PubMed","locations":["China","Wuhan","Hubei","Sarbecovirus"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Transmission","Mechanism"],"weight":1,"_version_":1663352134793428993,"score":184.4657},{"pmid":32235945,"title":"Virological assessment of hospitalized patients with COVID-2019.","text":["Virological assessment of hospitalized patients with COVID-2019.","Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 2019(1,2). Initial outbreaks in China involved 13.8% cases with severe, and 6.1% with critical courses(3). This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung(2,4). By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity, but also aided the control, of severe acute respiratory syndrome (SARS) in 2003(5). However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting the potential for pre- or oligosymptomatic transmission(6-8). There is an urgent need for information on body site-specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 x 10(8) RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples, in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat and lung samples from the same patient, proving independent replication. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (14 days in all), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts the prospects of COVID-19 containment in perspective.","Nature","Wolfel, Roman","Corman, Victor M","Guggemos, Wolfgang","Seilmaier, Michael","Zange, Sabine","Muller, Marcel A","Niemeyer, Daniela","Jones, Terry C","Vollmar, Patrick","Rothe, Camilla","Hoelscher, Michael","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Ehmann, Rosina","Zwirglmaier, Katrin","Drosten, Christian","Wendtner, Clemens","32235945"],"abstract":["Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 2019(1,2). Initial outbreaks in China involved 13.8% cases with severe, and 6.1% with critical courses(3). This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung(2,4). By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity, but also aided the control, of severe acute respiratory syndrome (SARS) in 2003(5). However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting the potential for pre- or oligosymptomatic transmission(6-8). There is an urgent need for information on body site-specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 x 10(8) RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples, in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat and lung samples from the same patient, proving independent replication. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (14 days in all), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts the prospects of COVID-19 containment in perspective."],"journal":"Nature","authors":["Wolfel, Roman","Corman, Victor M","Guggemos, Wolfgang","Seilmaier, Michael","Zange, Sabine","Muller, Marcel A","Niemeyer, Daniela","Jones, Terry C","Vollmar, Patrick","Rothe, Camilla","Hoelscher, Michael","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Ehmann, Rosina","Zwirglmaier, Katrin","Drosten, Christian","Wendtner, Clemens"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32235945","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41586-020-2196-x","source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1663352135585103872,"score":177.41753},{"pmid":32196410,"title":"Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.","text":["Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia.","Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed.","Emerg Microbes Infect","Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng","32196410"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed."],"journal":"Emerg Microbes Infect","authors":["Lin, Ling","Lu, Lianfeng","Cao, Wei","Li, Taisheng"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196410","week":"202012|Mar 16 - Mar 22","doi":"10.1080/22221751.2020.1746199","keywords":["COVID-19","IVIg","SARS-CoV-2","anticoagulation","pathogenesis"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663352133462786048,"score":176.69221}]}